Kalaris Therapeutics Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Kalaris Therapeutics.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

According to 1 stock analyst, the rating for Kalaris Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Apr '25
Strong Buy	0
Buy	1
Hold	0
Sell	0
Strong Sell	0
Total	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Lachlan Brown William Blair	William Blair	Buy Initiates n/a	Buy	Initiates	n/a	n/a	Apr 8, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.30

from -10.44

EPS Next Year

-0.45

from -0.30

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-
Revenue Growth	-	-	-	-	-	-
EPS	-3.48	-2.42	-10.44	-0.30	-0.45	-
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-
No. Analysts	-	-	-	6	4	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	n/a	n/a	n/a
Avg	n/a	n/a	n/a
Low	n/a	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

EPS Forecast

EPS	2025	2026
High	-0.05	-0.46
Avg	-0.30	-0.45
Low	-0.49	-0.43

EPS Growth

EPS Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.